Though colchicine has been famed for centuries for its effect in acute gouty arthritis its relief of pain and inflammation in this condition is not invariable and may not be apparent for 24 hours or more. It was therefore not surprising that when phenylbutazone was introduced colchicine was largely replaced by this preparation, which was more certain in its action. Highdosage phenylbutazone therapy, however, was occasionally associated with marrow depression (Mauer, 1955). In 1963 indomethacin was reported to be an effective anti-inflammatory agent in a number of rheumatic diseases (Katz et al., 1963; Norcross, 1963 ; Rothermrich, 1963). In acute gouty arthritis Hart and Boardman (1963) reported favourable results with the use of 300 mg. of indomethacin given in divided doses during the first 24 hours, with a gradual subsequent reduction to 100-150 mg. daily. The dose was varied from day to day according to the response, and treatment was continued for at least five days, or longer if symptoms persisted. Smyth et al. (1963) also obtained good results with indomethacin in acute gouty arthritis, using doses of 600-900 mg. on the first day and 400 mg. daily in divided doses during the next three to five days.
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It therefore seemed that indomethacin was useful in acute gouty arthritis, but that dosage schedules varied widely and needed frequent review. Thus there seemed a need for a standardized regimen of treatment which would be uniformly successful but simple enough to leave in the hands either of patients or of nursing staff without constant supervision, and which would vary inherently with the severity of the gout and the response. Such a schedule might well be comparable to the usual schedule of oral colchicine treatment, in which the dosage varied with the response and toxic effects. The above considerations therefore led to the choice of the following therapeutic regimen: 100 mg. of indomethacin four-hourly until most pain was relieved, then 100 mg. eight-hourly for 24 hours, then 75 mg. eight-hourly for 24 hours, and then 50 mg. eighthourly for 24 hours.
This regimen was tested for effectiveness in patients with acute gouty arthritis. At the same time undesirable side-effects were sought and opportunities were taken to determine whether improvement in the regimen, such as a reduction in dosage, was possible.
Patients Twenty-two patients (see accompanying Table) were treated with the above regimen over a period of two years. Initially, patients were observed in hospital, where regular assessment of response was made. Later a few were treated as outpatients and came to the hospital daily for assessment. The severity of the arthritis in this group varied greatly, but a large proportion had severe gout and had been referred because of difficulty in control of hyperuricaemia. In half of the patients more than one joint was acutely inflamed.
Results
There was a rapid and striking response to this regimen of treatment with indomethacin, details of which are shown in the 
Side-effects
Patients were asked whether the indomethacin tablets had upset them in any way, and were later specifically questioned about symptoms of headache, giddiness, faintness, nausea, vomiting, dyspepsia, and diarrhoea. Out of the 22 patients only four developed headache during the treatment; one of these thought that the relief of the gout was fair compensation for the headache, and two commented that they " often got headaches, anyway." One patient admitted to slight giddiness during treatment; two complained of " indigestion " and one of nausea when the indomethacin was taken on an empty stomach, with relief when taken after food. No patient was known to have a peptic ulcer. One patient noticed impairment of his capacity for mental concentration. Another (Case 20) developed vomiting and giddiness after 500 mg. of indomethacin, which was thereupon stopped. When his gout recurred 16 hours later he took a course of 1,325 mg. without further symptoms.
Because of the reported association with peptic ulceration (Norcross, 1963; Lovgren and Allander, 1964) , the indo-methacin capsules were given whenever possible with food, but antacids were used only if epigastric discomfort occurred. Tests for faecal occult blood (chiefly using Haematest tablets) wered carried out on any faeces passed. As Robinson, 1965 Nelson, 1966) , the only other specific study of the use of indomethacin in gout is that of Boardman and Hart (1965) (1965) reported no response to indomethacin in four females with gout, but the two females in the group under study responded in a manner quite indistinguishable from that of the males-again the difference in response may be one of dosage. It would seem that the higher the dosage used the more rapid the response and the greater the proportion of patients responding. The factors limiting dosage then become the cost and the incidence of side-effects.
Reports of the use of indomethacin in other joint diseases Smyth, 1965) have included a high incidence of headache, giddiness, nausea, or vomiting. The incidence seemed to depend largely upon the daily dose of indomethacin administered, ranging from 30 to 80% with daily doses of 100 to 200 mg. This trial has therefore been unusual for the low incidence of side-effects found. Boardman and , using doses which sometimes reached 600 mg. daily, found a 30% incidence of side-effects in their gouty patients ; they also commented that these were not severe. Their lower dosage was therefore not associated with any reduction in the incidence of side-effects, though they thought that sideeffects were less severe in younger patients. It seems possible that patients with acute gout, who are relatively young and otherwise healthy, may be more tolerant of the side-effects of indomethacin than patients suffering from a chronic debilitating disease such as rheumatoid arthritis.
Summary
The results of treatment with a regimen of indomethacin therapy in 22 patients with acute gouty arthritis are described. The regimen consisted in administering 100 mg. of irndomethacin by mouth four-hourly until most of the pain was relieved, after which administration was continued at eighthourly intervals with three doses of 100 mg., three of 75 mg.,, and three of 50 mg. This method has been shown to be very effective in producing rapid relief of pain and subsidence of the acute gouty arthritis and to be associated with a low incidence of side-effects.
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The facial flushing associated with the consumption of alcohol is a well-recognized phenomenon, and alcohol, often in the form of whisky, has been widely recommended as a useful peripheral vasodilator agent. There have been very few quantitative measurements reported of its effects on peripheral blood-flow in normal subjects, however (Abramson et al., 1941) , and none in subjects with ischaemic legs, though intra-arterial alcohol therapy has been described (Edwards et al., 1952; Conrad and Green, 1964 
Methods
Blood-flow in the feet, calves, forearms, and wrists of healthy adult subjects, and of patients with occlusive arterial disease affecting the legs, was measured by venous occlusion plethysmography by means of mercury in rubber-strain gauges (Whitney, 1949) . Plethysmograms from the wrist and foot are a record mainly of skin blood-flow, while those from the forearm and calf indicate largely muscle blood-flow. Blood-flow in the upper limb was also measured in patients after cervicodorsal sympathectomy for Raymond's phenomenon and hyperhidrosis. In all subjects alcohol was given either orally, in the form of Scotch whisky in a dose varying from 1 to 3 ml./kg. of body weight, or as a brachial-artery infusion of ethyl alcohol from a motordriven syringe.
In each experiment the subject, after a light meal, lay for approximately half an hour in the laboratory until his peripheral blood-flow was at a steady level. 
